益丰药房(603939) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥5,181,484,438.58, representing a year-on-year increase of 12.70%[3] - The net profit attributable to shareholders for the same period was ¥294,030,212.68, reflecting an 18.96% increase compared to the previous year[3] - The basic earnings per share for Q3 2023 was ¥0.29, up by 20.83% year-on-year[3] - Total operating revenue for the first three quarters of 2023 reached ¥15,888,047,446.63, an increase of 19.0% compared to ¥13,347,637,915.32 in the same period of 2022[24] - Net profit for the third quarter of 2023 was ¥1,128,268,629.45, representing a 23.1% increase from ¥916,526,052.63 in the same quarter of 2022[25] - The total comprehensive income for the third quarter of 2023 reached CNY 1,213,134,172.99, an increase from CNY 874,012,181.80 in the same period last year, representing a growth of approximately 38.8%[26] - Basic earnings per share for the third quarter of 2023 was CNY 0.99, compared to CNY 0.82 in the previous year, reflecting a year-over-year increase of 20.7%[26] Assets and Liabilities - Total assets at the end of the reporting period reached ¥21,935,278,533.96, marking a 4.26% increase from the end of the previous year[4] - The company's total assets as of the end of Q3 2023 amounted to ¥21,935,278,533.96, compared to ¥21,038,886,640.04 at the end of Q3 2022, reflecting a growth of 4.3%[21] - The total liabilities for Q3 2023 were ¥11,916,049,937.44, slightly down from ¥11,917,419,653.19 in Q3 2022[20] - The equity attributable to shareholders increased to ¥9,389,512,616.60, which is a 9.74% rise compared to the previous year[4] - The company's equity attributable to shareholders reached ¥9,389,512,616.60, an increase of 9.7% from ¥8,556,078,527.92 in the previous year[21] Cash Flow - The cash flow from operating activities for the year-to-date was ¥2,881,891,859.25, showing a 24.86% increase[3] - Cash inflow from operating activities for the first nine months of 2023 was CNY 17,558,038,342.56, up from CNY 14,172,638,927.69 in the same period of 2022, indicating a growth of about 23.5%[29] - The net cash flow from operating activities for the first nine months of 2023 was CNY 2,881,891,859.25, compared to CNY 2,308,090,112.73 in the previous year, marking an increase of approximately 25%[29] - The total cash and cash equivalents at the end of the third quarter of 2023 was CNY 2,508,036,101.09, slightly up from CNY 2,453,607,708.15 at the end of the same period last year[30] - The company reported cash and cash equivalents of RMB 3,499,950,576.74 as of September 30, 2023, down from RMB 4,112,519,204.66 at the end of 2022[18] Store Expansion and Acquisitions - In the first nine months of 2023, the company added 2,240 stores, including 1,046 self-built stores, 368 acquired stores, and 826 franchise stores, bringing the total number of stores to 12,350[12] - The company completed 9 mergers and acquisitions in the industry from July to September 2023, with 4 projects finalized[13] - The acquisition of 60% equity in Yichun Laobaixing Pharmaceutical Chain Co., Ltd. was completed for a transfer price of RMB 24.6 million, involving 30 stores[13] - The acquisition of 80% equity in Hebei Baixin Kang Pharmaceutical Chain Co., Ltd. was completed for a transfer price of RMB 23.344 million, involving 58 stores[13] - The company is in the process of acquiring 70% equity in Chengde Baixing Pingjia Pharmacy Chain Co., Ltd. for a transfer price of RMB 26.74 million, involving 19 stores[16] - The company plans to acquire assets from Jiangling County Miaoyuan Pharmacy and 10 other pharmacies for a maximum cash price of RMB 6.88 million[16] - The company has a total of 2,788 franchise stores included in the total store count[12] - The company is actively pursuing market expansion through both organic growth and strategic acquisitions[13] Research and Development - Research and development expenses for the first three quarters of 2023 were ¥15,256,402.00, compared to ¥13,769,981.10 in the same period of 2022, indicating a growth of 10.8%[24] - The company has not disclosed any new product developments or market expansion strategies in the current report[2] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[25] Investment Income - The company reported a significant increase in investment income, which rose to ¥36,247,328.63 in Q3 2023 from ¥7,327,701.97 in Q3 2022[25] - The company received CNY 14,501,228.50 from investment activities in the first nine months of 2023, a decrease from CNY 84,000,952.00 in the previous year[30]